Nasdaq:US$15.81 (-0.23) | HKEX:HK$24.40 (-0.45) | AIM:£2.61 (+0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.